# Alebund Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alebund-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.alebund.com
- Total disclosed funding: $190M
- Latest round: Series C (Jan 7, 2025)
- Investors on record: 15

## About

Established in 2018 and based in Shanghai, China, Alebund Pharmaceuticals is a biopharmaceutical company that engages in the research and development of drugs for kidney diseases and related chronic diseases. The company's co-founder and CEO, Gavin Xia, received a PhD from the University of Chicago and has more than 15 years of experience in drug development in the healthcare industry. In January 2025, Alebund Pharmaceuticals raised CNY 550 million in series C funding.

Alebund Pharmaceuticals is engaged in the research and development of new treatments for kidney disease and its complications and other chronic diseases. It has established a new drug product pipeline for kidney disease, including products for chronic kidney disease (CKD)/dialysis complications, IgA nephropathy, diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), autosomal dominant polycystic kidney disease (ADPKD), etc.

The company generates revenue by developing new renal drug products targeting chronic kidney disease (CKD)/dialysis complications.

The company will use the series C funding to advance the development and commercialization of its renal disease pipeline and accelerate the advancement of multiple clinical programs.

## Funding rounds

- Series C, Jan 7, 2025, $75M — Kingray Capital, Yangzhou International Finance Investment
- Series B, Sep 14, 2021, $55M — Lilly Asia Ventures, 5Y Capital, Verition Fund Management, YuanBio Venture, 3E Bioventures Capital, Loyal Valley Capital, Quan Capital, Sherpa Healthcare Partners, 3H Health Investment, HT Capital, Octagon Capital Investments
- Series B, May 10, 2021, $60M — Lilly Asia Ventures, 3E Bioventures Capital, MED-FINE Capital, Quan Capital, Sherpa Healthcare Partners
- Series A, Dec 25, 2020 — Lilly Asia Ventures, Huagai Capital, MED-FINE Capital

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A, Series B
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- Verition Fund Management — Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series B
- 3H Health Investment (https://capitalatlas.ai/funds/3h-health-investment) — Series B
- HT Capital — Series B
- Octagon Capital Investments (https://capitalatlas.ai/funds/octagon-capital-investments) — Series B
- Kingray Capital (https://capitalatlas.ai/funds/kingray-capital) — Series C
- Yangzhou International Finance Investment — Series C